Quick Answer
Denali Therapeutics Inc. reported Operating Income Loss of -$555.34 million for the year ending 2025.
- Denali Therapeutics Inc. showed a decrease of -14.0% in Operating Income Loss from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Denali Therapeutics Inc.'s Operating Income Loss has declined by 535.2%.
- Historical annual values: Fiscal year 2025: -$555.34 million | Fiscal year 2024: -$487.34 million | Fiscal year 2023: -$196.70 million | Fiscal year 2022: -$340.74 million | Fiscal year 2021: -$295.75 million | Fiscal year 2020: $62.72 million | Fiscal year 2019: -$213.18 million | Fiscal year 2018: -$46.37 million | Fiscal year 2017: -$90.14 million | Fiscal year 2016: -$87.43 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: